The global artificial pancreas device market, estimated at USD 334.76 million in 2024, is projected to grow significantly at a CAGR of 16.33% between 2025 and 2032, ultimately reaching USD 1,116.86 million by 2032. Market expansion is primarily fueled by the escalating global burden of diabetes, which continues to drive demand for advanced and automated glucose management technologies. Greater awareness, increased diagnostic efforts, and wide-scale screening programs have enabled earlier intervention and improved disease control, further supporting the uptake of artificial pancreas systems. Additionally, ongoing advancements and innovation by major industry players have led to more user-friendly, accurate, and efficient devices, contributing to better therapeutic outcomes. These combined factors are expected to sustain market momentum throughout the forecast period.
DelveInsight’s Artificial Pancreas Device Market Insights report offers comprehensive current and future market evaluations, detailed market share analyses of top companies, key growth drivers, challenges, barriers, trends, and profiles of prominent players in the artificial pancreas device landscape.
Request for a sample page report @ https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Artificial Pancreas Device Market Report
The Artificial Pancreas Device market is expected to expand at a steady CAGR between 2025 and 2032. DelveInsight forecasts that North America will remain the leading region in the global market throughout the study period.
Several key companies are active in the Artificial Pancreas Device space, including Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., Bigfoot Biomedical, Inc., CamDiab Ltd., Diabeloop SA, Ypsomed, Inreda® Diabetic B.V., Nikkiso Co., Ltd., Pancreum, Inc., Johnson & Johnson Services, Inc., Dexcom, Inc., TypeZero Technologies, Animas Corporation, among others.
Recent noteworthy updates include:
-
September 2024: Tandem Diabetes Care, Inc. received EU clearance for its t:slim X2 insulin pump with Control-IQ automated insulin delivery technology to be used alongside Eli Lilly’s ultra-rapid-acting insulin Lyumjev® (insulin lispro-aabc).
-
June 2024: MCRA, a major independent CRO, announced its role in assisting CamDiab’s artificial pancreas software, CamAPS FX, in obtaining FDA clearance.
To read more about the latest highlights related to the Artificial Pancreas Device market, get a snapshot of the key highlights entailed in the Global Artificial Pancreas Device Market Report
Artificial Pancreas Device Overview
Artificial pancreas devices are sophisticated systems developed to automate glucose regulation for people living with diabetes, especially those with type 1 diabetes. These solutions combine three essential elements—a continuous glucose monitor (CGM), an insulin pump, and an algorithm-driven controller—to replicate the glucose-regulating function of a healthy pancreas by tracking glucose levels continuously and adjusting insulin delivery automatically.
The main objective of artificial pancreas technology is to maintain stable blood glucose levels, minimize episodes of hyperglycemia and hypoglycemia, and reduce the daily management burden associated with diabetes. Compared with conventional insulin therapies such as multiple daily injections, these systems offer superior clinical outcomes, better treatment adherence, and enhanced quality of life.
Artificial pancreas devices are particularly beneficial for children, adolescents, and adults with type 1 diabetes, as well as for expectant mothers with gestational diabetes. Continuous improvements in closed-loop technology, compatibility with different insulin formulations, and integration with mobile devices are further accelerating global adoption.
With diabetes cases rising worldwide, greater awareness of advanced diabetes management solutions, and increasing regulatory support, artificial pancreas devices are emerging as a game-changing technology poised for substantial growth in the near future.
Artificial Pancreas Device Market Insights
North America is expected to lead the artificial pancreas device market in 2024, accounting for the largest regional share. This dominance is supported by a rising diabetes population, robust government healthcare initiatives, active participation of major industry players in product innovation, and growing public awareness of advanced diabetes management technologies.
The CDC (2024) reported that about 38.4 million Americans—11.6% of the total population—were living with diabetes. Of these, 38.1 million were adults aged 18 and older, representing 14.7% of the adult population in 2021. The increasing prevalence of diabetes, especially type 1 diabetes, underscores the need for advanced tools that simplify glucose control. Artificial pancreas systems, which automatically regulate insulin based on continuous glucose readings, help improve outcomes and reduce the daily burden of disease management, thereby driving regional market demand.
Educational initiatives are also fueling adoption. Programs led by the NIH and CDC, such as the National Diabetes Education Program (NDEP), aim to raise awareness of continuous glucose monitoring and automated insulin delivery technologies, including artificial pancreas solutions.
In addition, technological and regulatory progress is further boosting the market. A key example is the FDA’s approval in May 2024 of the CamAPS FX artificial pancreas—developed by the University of Cambridge—for individuals with type 1 diabetes aged two years and older, including pregnant women.
To know more about why North America is leading the market growth in the Artificial Pancreas Device market, get a snapshot of the Artificial Pancreas Device Market Outlook
Artificial Pancreas Device Market Dynamics
Recent data from the International Diabetes Federation (IDF) shows that approximately 537 million adults aged 20–79 were living with diabetes globally in 2021. This number is projected to increase to 643 million by 2030 and reach 783 million by 2045.
According to the IDF Diabetes Atlas (2022), of the 8.75 million people worldwide with type 1 diabetes, 1.52 million were younger than 20 years old. Notably, 62% of new type 1 diabetes cases in 2022 were diagnosed in individuals aged 20 or older. Since diabetes requires continuous monitoring and precise insulin control, artificial pancreas systems—which combine insulin pumps with continuous glucose monitoring (CGM) to automate insulin delivery—represent a significant improvement in patient care and overall quality of life.
Hyperglycemia during pregnancy is another growing concern, as it increases risks for both mother and baby, including preterm birth, macrosomia, and preeclampsia. The IDF (2025) reported that around 21.1 million live births (16.7%) were affected by high blood glucose levels during pregnancy. Women over 45 and those with a history of gestational diabetes are also at greater risk of developing type 2 diabetes later in life. Maintaining steady glucose levels is therefore essential for safe pregnancies. However, traditional management approaches such as multiple daily insulin injections can be challenging due to hormone-driven fluctuations that cause unstable glucose levels. Artificial pancreas devices, which use CGM data to automate insulin dosing, offer a more reliable way to maintain glucose stability with minimal manual effort—supporting increased adoption and contributing to global market growth.
Artificial Pancreas Device Market Drivers:
-
Rising cases of diabetes
-
Rising awareness and screening programs
-
Increase in product development activities across the globe
Get a sneak peek at the Artificial Pancreas Device market dynamics
Scope of the Artificial Pancreas Device Market Report:
-
Coverage: Global
-
Study Period: 2022 to 2032
-
Key Artificial Pancreas Device Companies: Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., BIGFOOT BIOMEDICAL, INC., CamDiab Ltd., Diabeloop SA, Ypsomed, INREDA® DIABETIC B.V., Nikkiso Co., Ltd., Pancreum, Inc., Johnson & Johnson Services, Inc., Dexcom, Inc., TypeZero Technologies, Animas Corporation, and others.
Which MedTech key players in the Artificial Pancreas Device market are set to emerge as the trendsetter, explore @ Artificial Pancreas Device Companies
About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/